Navigation Links
Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
Date:1/23/2008

- Second filing provides opportunity for additional indications and

increased potential market -

PLYMOUTH MEETING, Pa., Jan. 23 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that the investigational new drug (IND) application submitted to the US Food and Drug Administration (FDA) for trodusquemine (MSI-1436) in type 2 diabetes is now in effect. This application represents the second IND filed by the Company in 2007 for MSI- 1436. A previous IND for the treatment of obesity, under which Genaera is currently conducting phase 1 clinical trials, has been in effect since April 2007. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which acts by regulating insulin and leptin receptor signaling through inhibition of the tyrosine phosphatase, PTP-1B.

"A growing body of data indicates that inhibition of PTP-1B is central to controlling the key pathologies associated with type 2 diabetes; namely insulin sensitivity and obesity," said Jack Armstrong, President and Chief Executive Officer of Genaera. "Since MSI-1436 has demonstrated significant potential to impact both the insulin and leptin pathways, we believe this new IND provides us with the opportunity for additional indications and a much broader potential market. Therefore, we are implementing a clinical plan which evaluates the drug's potential in type 2 diabetes, in addition to our ongoing obesity studies. With this dual strategy, we believe that we are well-positioned to maximize the therapeutic potential of MSI-1436."

In October 2007, Genaera completed the first phase 1 study of MSI-1436 in healthy obese and overweight subjects. MSI-1436 is currently being evaluated in a second pha
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
3. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
5. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
6. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)...  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), a specialty ... innovative therapies for the treatment of acute and breakthrough ... chief financial officer  will be participating in three upcoming ... Mizuho Third Annual Healthcare Corporate Access Day ... New York Bank ...
(Date:4/30/2015)... April 30, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. ... with a focus on Omega-3 therapies for cardiovascular ... highlights and financial results for the fiscal year ... herein are in Canadian dollars unless otherwise stated. ... significant, with the right strategic partners and additional ...
(Date:4/30/2015)... April 30, 2015  Accuray Incorporated (Nasdaq: ... an agreement with MIM Software Inc. to further ... and CyberKnife ® product portfolios. The new ... technology. This is Accuray,s second collaboration with MIM; ... the first iPad-based treatment plan review capability, PlanTouch™. ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
... COLD SPRING HARBOR, N.Y. , May 18 AccuVein ... Medipath Division of Morepen Laboratories to sell the AV300 vein finder in ... signed 30 distributors worldwide. , , ... AccuVein AV300 helps healthcare professionals locate veins for blood draw , ...
... , WINTER PARK, Fla. , May 18 ... cataract surgery and presbyopia, today announced that the company has received ... System for anterior capsulotomy during cataract surgery.   , ... The LensAR Laser System integrates ...
Cached Medicine Technology:AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 2AccuVein Signs Exclusive Distribution Agreement in India to Sell Vein Illumination Device 3LensAR Laser System(TM) Receives FDA Clearance for Use in Cataract Surgery 2
(Date:5/1/2015)... Providenciales, Turks and Caicos Islands, BWI (PRWEB) May 02, ... has a new website! It is http://www.thevenetiangracebay.com ... resort itself, and it incorporates the stunning white and ... "According to a study of Google, sixty seven percent ... process. The study showed that smartphones were used ...
(Date:5/1/2015)... 2015 Jusuru International has been awarded ... repositioning of its flagship nutritional supplement, Liquid BioCell™ Life, ... new name, new logo, new packaging, new products, and ... designed to identify and promote programs that serve as ... “DSA congratulates Jusuru International for their outstanding accomplishments and ...
(Date:5/1/2015)... 2015 The Workgroup for Electronic ... on the use of health IT to create efficiencies ... resource to the United States Government Accountability Office (GAO) ... cards in Medicare. The report, “ Potential Uses of ... released to the public on Apr. 24, 2015 and ...
(Date:5/1/2015)... 01, 2015 It’s raining bills on Capitol ... proposals to expand federal support for telemedicine. , ... has been working with Congress,” said Jonathan Linkous, CEO of ... the nation is poised to embrace the use of telecommunications ... step in fulfilling ATA’s mission to improve quality, access, equity ...
(Date:5/1/2015)... KY (PRWEB) May 01, 2015 Ernst ... CEO, Dr. Joshua Rosenthal, Co-Founder & CSO, and Burak ... finalists for the EY Entrepreneur Of The Year® ... Ernst & Young is a global leader in ... to be one of the top audit companies ...
Breaking Medicine News(10 mins):Health News:Turks and Caicos Resort, The Venetian on Grace Bay, Launches New Web Presence 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 2Health News:WEDI Contributes to Newly Released U.S. Government Accountability Office (GAO) Study on Potential Use of Electronically Readable Medicare Cards 3Health News:ATA: Congress Floods the Halls with Telemedicine Proposals 2Health News:RowdMap, Inc. Named as a Ernst & Young Entrepreneur Of The Year® 2015 Award Finalist 2
... -- The worldwide incidence of cancer is expected to increase ... than 90 percent in the poorest nations, a new study ... cervical and stomach cancer) appear to be declining in some ... by substantial increases in the types of cancer associated with ...
... , THURSDAY, May 31 (HealthDay News) -- More than ... new government report shows. "Untreated tooth decay is ... Dye, an epidemiologist at the U.S. Centers for Disease ... appears that we haven,t been able to make any ...
... Four University of Houston (UH) students are well on their ... this spring in their work toward new therapies for prostate ... Center for Nuclear Receptors and Cell Signaling (CNRCS), these students ... and expressed, which is vital in developing treatments for cancer. ...
... Philadelphia National data show that currently more than ... obese, and an additional 10 percent are overweight. In ... School of Medicine at the University of Pennsylvania, in ... says that effective strategies to target pregnancy, infancy, and ...
... icon of cleanliness for home and commercial kitchens, restaurants, ... bacteria like other surfaces if not cleaned often. Scientists ... Langmuir , of a practical way to make stainless ... explain that while stainless steel is prized for its ...
... THURSDAY, May 31 (HealthDay News) -- When men are ... their future fertility than women, new Scottish research says. ... information provided to young women diagnosed with cancer and ... fertility expert," study co-author Valerie Peddie, a fertility nurse ...
Cached Medicine News:Health News:Worldwide Cancer Incidence Predicted to Rise 75% by 2030 2Health News:1 in 5 Americans Has Untreated Cavities: CDC 2Health News:Student researchers seek to develop new therapies for cancer 2Health News:Student researchers seek to develop new therapies for cancer 3Health News:Researchers call for obesity prevention efforts to focus on community-wide systems 2Health News:Men and Women With Cancer May Receive Different Fertility Information 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: